Recorded Presentation from the New NCCN Guidelines for Pediatric Cancers: Key Considerations for the Management of Pediatric Hodgkin Lymphoma
The NCCN Guidelines for pediatric Hodgkin lymphoma were created to help define optimal clinical care for these patients. Continuing education on emerging developments in this arena will help ensure that clinicians are aware of how best to incorporate these strategies, which may enhance care and outcomes for patients with pediatric Hodgkin lymphoma.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Clinicians must understand the treatment evolution and guidelines for administration of available therapies in the context of the patient's therapeutic and disease history to navigation through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date March 3, 2021
Recorded Presentation from the NCCN Pharmacy Updates: Emerging Strategies in the Treatment of Venous Thromboembolism
Expanded indications for the use of the direct oral anticoagulants demand diligent monitoring. Health care professionals play a crucial role in the management of anticoagulation in cancer patients and anticoagulation monitoring clinics may need to rechannel resources to include these agents.
Category
  • Venous Thromboembolic Disease
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Pharmacists should be aware of data on targeted therapy and immunotherapy for RCC and be able to make appropriate therapy recommendations. In addition, pharmacists play an important role in the management of toxicity of targeted therapy or immunotherapy and encouraging compliance for patients on targeted therapies for RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Adjuvant and Neoadjuvant Therapies for Early Stage Breast Cancer, Including SABCS Updates
Clinicians are challenged to stay up-to-date on new approaches and options for neoadjuvant /adjuvant systemic therapy so they can provide appropriate care using a shared decision making process with the patient, taking into account patient and disease characteristics including risk of recurrence, and weighing the potential benefits and risks of each option. In addition, it is important for clinicians to be aware of new supportive care interventions available to improve the quality of life of patients.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Assays for Treatment Selection of Advanced Breast Cancer
Biomarkers identify patients who are likely to respond to a given therapy. These assays and their interpretation can present challenges for clinicians.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Genetics/Familial Risk Assessment for Breast Cancer: Controversies and Evolving Principles
There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Is There a Role for Proton Therapy in the Treatment of Breast Cancer?
Locoregional management strategies have considerably evolved.  Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximize clinical benefit while minimizing toxicity; however, many controversies exist as we
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Metastatic Breast Cancer, Including SABCS Updates
The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages